Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. - Test2 - elhamkhani - TriplyDB

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

http://www.wikidata.org/entity/Q30738419

about

Control of adipocyte differentiation in different fat depots; implications for pathophysiology or therapy Phosphoinositides: Key modulators of energy metabolism PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty The current role of thiazolidinediones in diabetes management.Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease Liver fat percent is associated with metabolic risk factors and the metabolic syndrome in a high-risk vascular cohort ISL1 regulates peroxisome proliferator-activated receptor γ activation and early adipogenesis via bone morphogenetic protein 4-dependent and -independent mechanisms.Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).Insulin sensitisation in the treatment of Type 2 diabetes.The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.Thiazolidinediones -- some recent developments.Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study.Rosiglitazone RECORD study: glucose control outcomes at 18 months.Fat in the liver and insulin resistance.Recent findings concerning thiazolidinediones in the treatment of diabetes.Bone density testing in clinical practice.Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production.The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.Increased Circulating Adiponectin in Response to Thiazolidinediones: Investigating the Role of Bone Marrow Adipose Tissue Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT.Adipocyte JAK2 mediates growth hormone-induced hepatic insulin resistance AMP-activated protein kinase and metabolic control.The growing challenge of obesity and cancer: an inflammatory issue.Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.PPARγ signaling and emerging opportunities for improved therapeutics.Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.Current and novel therapies for the treatment of nonalcoholic steatohepatitis.Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes.Rosiglitazone Improves Insulin Resistance Mediated by 10,12 Conjugated Linoleic Acid in a Male Mouse Model of Metabolic Syndrome.Effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy: the Rosiglitazone Early Versus SULphonylurea Titration (RESULT) Study.Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging.Marine n-3 fatty acids promote size reduction of visceral adipose depots, without altering body weight and composition, in male Wistar rats fed a high-fat diet.Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone.Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes.

P2860

Q26825739-AF0201CE-C1FF-4B92-95C6-09482FFFB281 Q27022953-B32A6FD4-C1D1-4689-A75E-51E4FAECAAEC Q27024799-27901653-7283-42F3-B877-B672EB675DBE Q30250347-D62A365C-EDC2-4C33-9F86-43B0661CD7F6 Q33358112-53693175-8E41-4303-8362-7359790E12EA Q33607697-62880033-ABDF-4D91-A2AF-ACA2C769E276 Q33909796-F293007F-A7FD-4930-B42A-0C676ED5A24F Q33952051-EA5A18F8-30FC-4EF7-866E-CA154CE87A9F Q34298015-562A6A13-8C2A-45A9-939A-0658C5DD7555 Q34774079-FE13B527-A77E-4C90-A0FD-4B16E685114E Q35073317-831D473B-DE6E-4F91-807B-3218E7D2C6A0 Q35090416-8E70E02C-9E1B-4484-9454-5E6411290240 Q35164761-441915F5-BE52-4AB1-9141-9DC1F4975552 Q35597166-C1AE5FAC-DC79-4271-8CA3-44952AB548B5 Q35987411-565D088C-976C-432E-94E6-59B221923166 Q36265235-F5EA2D48-9C70-41FB-8663-431E08BC4ABE Q36407304-FABC358E-D389-4F4B-B05C-1249034FE039 Q36658910-0340A583-9D71-4445-912E-99552C212799 Q36976999-A06D22A0-25E7-45EF-BA80-3DD257E52B34 Q36993971-D847360A-B1EA-4C1F-BF98-072E0BC99122 Q37051264-E8B3ABE7-BC45-4593-8C67-FCCC33B4BE26 Q37270815-0705066C-2C7B-4370-B2CA-DBFA53227546 Q37311122-CCAB0990-2F4B-41E0-8365-E241553AADEC Q37547069-26B69AC5-CCFA-4664-99B9-32B957B7803C Q37624383-7E3E3D38-EE4E-4D35-9661-28A29A16BD07 Q37864217-ED2B1020-E591-407B-9666-203FE48FC464 Q37906706-38CCE854-A665-406F-AB62-F3E6C1E8F61D Q38588541-9CA27926-7ADE-4380-9D7B-1BCDBE88BF74 Q38641190-C4848BE5-546E-4D4D-BE24-0BE3B68C5204 Q38656970-B518275E-7A48-4368-9CCE-DA2AC4F3970F Q38856983-B12DB222-49CB-461D-9CE5-9226E58AFA81 Q41818240-80E0D272-7D06-4961-9CF8-B1A60B988A57 Q41832154-69AD9868-0914-49E8-895B-D44FFACA163D Q41931381-93DCBE8E-4EF4-469E-9668-53DE888B4218 Q42799582-A31B0CD6-B883-49FE-8BA3-49E04B9435F1 Q43202587-B327C822-E095-45D2-A9CD-E7BA97093658 Q43815610-1DE67ED1-A20C-4593-AA61-DA3943904C10 Q46034945-5A367E3C-8A00-471B-910B-54E3E953194F Q46140429-6168D84E-EB1B-4FD7-9967-7FBBB7642E92 Q46553591-D570B614-73E6-49E7-B64E-09BB6407BFF5

P2860

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

http://www.wikidata.org/entity/Q30738419

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Effect of rosiglitazone on ins ...... diabetic patients [corrected].

@ast

Effect of rosiglitazone on ins ...... diabetic patients [corrected].

@en

type

label

Effect of rosiglitazone on ins ...... diabetic patients [corrected].

@ast

Effect of rosiglitazone on ins ...... diabetic patients [corrected].

@en

prefLabel

Effect of rosiglitazone on ins ...... diabetic patients [corrected].

@ast

Effect of rosiglitazone on ins ...... diabetic patients [corrected].

@en

P1433

Q30738419-271A81D9-AA93-4347-B454-691F2B5E80FC

P1476

Q30738419-18663534-77D8-4DE4-8D72-1FA214FFF341

P2093

Q30738419-2756362C-C369-410A-BC5E-094B26E597F2

Q30738419-3C4DDD52-6A32-4976-B69B-513E2B26923A

Q30738419-3FA956C3-2DD9-4201-9531-C1B91D0F33BB

Q30738419-504141C8-580D-4877-93DC-E887140B88D9

Q30738419-61414E81-0256-4C01-AAD2-72F235B66F8D

Q30738419-B958FF02-B373-4F80-8497-FCE7C001AF07

Q30738419-EF90A683-0759-4848-9B80-7F7BD5E5DB16

P2860

Q30738419-086B868E-F0A0-45A3-8100-E00B01D78E80

Q30738419-0950E3CB-9CD7-417C-84B0-74EFEF195C5A

Q30738419-0FF1E2CC-9106-4D87-B63F-59D8FA19E90E

Q30738419-18503E2D-BE31-4804-84FC-C1352C0D5254

Q30738419-44F60C4E-7521-4DAE-BADA-ECB333BBF267

Q30738419-4B2C5047-5115-449F-91A0-96C75B9B3B9B

Q30738419-52B0FAED-35DF-40EF-93B0-566333A9CA9F

Q30738419-5A07BBBB-4AD2-4E6D-900C-8401A08259AB

Q30738419-79EB34B1-772F-4D45-98AA-5CDE149E0A52

Q30738419-7BC67DD8-0D7E-4BA3-A1DF-09B5F15E2ECE

P304

Q30738419-3AB46230-6B31-45CB-BF3C-98391D0714F3

P31

Q30738419-AD0459D6-A92D-4B55-82EE-8C16AA4D4867

P356

Q30738419-0F8A9464-D455-4722-8B7A-2F39F83BB448

P433

Q30738419-D1C8351B-76AF-4A73-8669-67E215C2D0CD

P478

Q30738419-AD84E9FE-CF3B-41AE-8692-E024E5D7012C

P577

Q30738419-CC8D2B26-3FB0-455A-8841-9C73FD42E0BD

P5875

Q30738419-07970D30-627F-4519-A6AB-0791B8344CD0

P698

Q30738419-C0127664-B0E7-424D-8DCA-BDFA7ECDCC03

P921

Q30738419-2216726A-DB73-4FFE-9FBE-258C97A3A3E0

P356

P1433

P1476

Effect of rosiglitazone on ins ...... diabetic patients [corrected].

@en

P2093

David G Carey

http://www.w3.org/2001/XMLSchema#string

David M Doddrell

http://www.w3.org/2001/XMLSchema#string

Gary J Cowin

http://www.w3.org/2001/XMLSchema#string

Graham J Galloway

http://www.w3.org/2001/XMLSchema#string

Jackie C Richards

http://www.w3.org/2001/XMLSchema#string

Nandita Biswas

http://www.w3.org/2001/XMLSchema#string

Nigel P Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.

Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

Relationships of generalized and regional adiposity to insulin sensitivity in men.

Metabolic implications of body fat distribution.

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

P304

1008-1015

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/OBY.2002.137

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11082770

http://www.w3.org/2001/XMLSchema#string

P698

12376581

http://www.w3.org/2001/XMLSchema#string

P921